Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda looks to be rather modest. We plan to promenade with the official mascot, support the local economy by taking in some of our favorite culinary treats, and catch up on our reading now that we renewed two library books for the fifth time (yes, we read slowly sometimes). And what about you? The temperatures may be brisk in some parts, but this remains a fine time to enjoy the great outdoors. Besides, exercise is important. You could convince someone to get vaccinated or do a mitzvah and check in on someone who feels isolated these days. Well, whatever you do, have a grand time. But be safe. Enjoy, see you soon. …

Alzheimer’s patient groups are planning publicity and lobbying campaigns to protest a Medicare coverage proposal they say could delay the use of new drugs for 10 years, Reuters writes. In a preliminary decision last week, the U.S. Centers for Medicare and Medicaid Services said it would cover the controversial Biogen (BIIB) drug called Aduhelm, and similar Alzheimer’s disease treatments being developed, only for patients enrolled in approved clinical trials. This would severely limit the number of patients receiving the treatment, undercutting U.S. Food and Drug Administration approval of Aduhelm for patients in the early stages of the condition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment